This page is not available in your chosen language. You can see English version of it.
Biotechnology startup Atrandi Biosciences, one of the world’s pioneers in advanced single-cell analysis technologies, has secured a $25 million Series A investment. The lead investor in this round is the U.S.-based venture capital firm Lux Capital, known for specializing in innovative technologies. Existing and new investors, including Vsquared Ventures, Practica Capital, Metaplanet, and GRIDS Capital, also participated in the funding round. This investment will accelerate the company’s expansion into the U.S. market, further develop its Semi-Permeable Capsule (SPC) technology, and drive new product development.
“When we founded Atrandi Biosciences in 2016, our goal was to remove fundamental barriers in biological research and create efficient, user-friendly tools for single-cell analysis,” said Dr. Juozas Nainys, CEO and co-founder of Atrandi Biosciences. “Our SPC technology revolutionizes single-cell analysis by enabling scientists to generate high-quality biological data. This investment will help us expand our product portfolio, strengthen our position in the U.S. market, and enhance customer support. Our mission is to provide scientists with cutting-edge tools that unlock new possibilities in biological research.”
The Role of Triniti Jurex in the Investment Deal
The Triniti Jurex team played a key role in this investment transaction, ensuring that all legal aspects were properly structured and aligned with international standards. The deal involved complex processes, such as the restructuring of convertible loans, share redistribution among founders and investors, and the issuance of new shares. Triniti Jurex experts collaborated with investors from the U.S., Germany, Estonia, and Lithuania to establish a transparent and sustainable legal structure, providing a clear growth plan and securing the company’s long-term expansion in the global market.
Atrandi Biosciences is the world’s first company developing Semi-Permeable Capsule (SPC) technology, enabling large-scale single-cell multiomics research. The company’s patented solutions simplify complex experimental processes and accelerate biological discoveries. Atrandi Biosciences’ mission is to provide scientists with advanced tools that enhance the understanding of life’s complexity and uncover previously unknown biological processes.
More information: https://atrandi.com/
